Stem Cell Therapy
Europe · 1 shared keyword
Updated
Reviewed by Chandani Patel
Europe Newborn Genome Sequencing Market Industry Trends and Forecast to 2034: Segmented by (Program, Condition, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$340.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $74.8 Mn | — | — |
| 2025 (base) | $89.1 Mn | +$14.3 Mn | — |
| 2026 (forecast) | $106.1 Mn | +$17.0 Mn | +19.1% |
| 2027 (forecast) | $126.4 Mn | +$20.3 Mn | +41.8% |
| 2028 (forecast) | $150.5 Mn | +$24.1 Mn | +68.9% |
| 2029 (forecast) | $179.2 Mn | +$28.7 Mn | +101.2% |
| 2030 (forecast) | $213.5 Mn | +$34.2 Mn | +139.6% |
| 2031 (forecast) | $254.2 Mn | +$40.8 Mn | +185.4% |
| 2032 (forecast) | $302.8 Mn | +$48.6 Mn | +239.9% |
| 2033 (forecast) | $360.6 Mn | +$57.8 Mn | +304.8% |
| 2034 (forecast) | $429.5 Mn | +$68.9 Mn | +382.2% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $89.1 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $429.5 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 19.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Program, condition and end user (see all) |
| Key players | Illumina, Inc., GeneDx, Natera, Genomics England, Fulgent Genetics (see all) |
| Regulator in Europe | EMASource: European Medicines Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Newborn genome sequencing reads a baby's DNA to find treatable genetic conditions early, beyond standard newborn screening.
Key segments of the newborn Genome Sequencing market include program (Research Programs, National Screening Pilots and Private Testing) and condition (Metabolic, Immune and Neurological).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the newborn Genome Sequencing market.
Routine use of genomics in screening, pharmacy and primary care gives the newborn Genome Sequencing market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the newborn Genome Sequencing market.
The newborn Genome Sequencing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8]
[1] European Medicines Agency. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] European Commission, health technology assessment. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for newborn Genome Sequencing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
What doctors and scientists are doing in Newborn Genome Sequencing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe
Europe
Europe
Europe
Digital Health · Europe
Healthcare Services · Europe
Healthcare Services · Europe
Medical Devices · Europe
Digital Health · Europe
Medical Devices · Europe